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Abstract
Background: An illness staging model for anorexia nervosa (AN) has received increasing attention, but assessing
the merits of this concept is dependent on empirically examining a model in clinical samples. Building on
preliminary findings regarding the reliability and validity of the Clinician Administered Staging Instrument for
Anorexia Nervosa (CASIAN), the current study explores operationalising CASIAN severity scores into stages and
assesses their relationship with other clinical features.
Method: In women with DSM-IV-R AN and sub-threshold AN (all met AN criteria using DSM 5), receiver operating
curve (ROC) analysis (n = 67) assessed the relationship between the sensitivity and specificity of each stage of the
CASIAN. Thereafter chi-square and post-hoc adjusted residual analysis provided a preliminary assessment of the
validity of the stages comparing the relationship between stage and treatment intensity and AN sub-types, and
explored movement between stages after six months (Time 3) in a larger cohort (n = 171).
Results: The CASIAN significantly distinguished between milder stages of illness (Stage 1 and 2) versus more severe
stages of illness (Stages 3 and 4), and approached statistical significance in distinguishing each of the four stages
from one other. CASIAN Stages were significantly associated with treatment modality and primary diagnosis, and
CASIAN Stage at Time 1 was significantly associated with Stage at 6 month follow-up.
Conclusions: Provisional support is provided for a staging model in AN. Larger studies with longer follow-up of
cases are now needed to replicate and extend these findings and evaluate the overall utility of staging as well as
optimal staging models.
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Plain English summary
Anorexia nervosa (AN) is an illness with a broad
spectrum of severity. Accessing and triaging treatment
matched to stage of illness remains a problem for people
with the illness, hence much attention has been paid to
the development of a model to stage the illness based on
the severity of symptoms. In this study, the severity score
provided by a standardised clinical interview assessing the
key symptoms of AN, was used to determine stage of
illness (stage 1 through to 4) across the AN spectrum, and
then examined for the validity of the stages and their
ability to predict outcome in 171 people. The stage
scores derived from the instrument could differentiate
between mild and more severe forms of illness and
did predict short-term outcome. Further research in
larger samples is required.
Background
The use of clinical staging as a method for operationalis-
ing severity is widespread in the medical disorders includ-
ing malignancies, cardiac failure, autoimmune diseases
and burns to name a few [1] (See Maguire et al., in Latzer,
2010 for review). It is a proven strategy in these disorders
where both prognosis and treatment are guided by stage
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[2]. This is because clinical staging has been argued as a
more refined form of diagnosis [3, 4] allowing an individ-
ual to be placed at any point in time along a continuum of
illness and defining the extent of illness at that time point
[5]. Staging can also frame an illness in such a way as to
naturally highlight opportunities for early intervention to
prevent illness progression, and to match treatments to
stages of severity.
In recent years a growing group of clinicians and
researchers have argued for staging to be adopted as part
of the diagnostic system for mental illnesses [3, 4, 6]. As
a result, a number of models of staging of mental disor-
ders have been tentatively proposed, including those for
mood disorders [7, 8], panic disorder [9] alcohol use dis-
orders [10], and schizophrenia [11]. Four stage models
of illness severity in mental illness are the norm (for a
recent systematic review see Cosci and Fava [12], where
four stage models for schizophrenia, uni and bipolar
depression, alcohol use and panic attacks are summarised).
Arguably the field of staging has been influenced by the
seminal and most successful disease staging model – the
Tumour, Node, Metastatsis (TNM) for cancer, utilising a
four stage model roughly equating to mild, moderate,
severe and extremely severe stages.
Anorexia nervosa (AN) is often referred to as an ill-
ness of varying levels of severity expressed on a con-
tinuum [13–19]. Indeed, a growing body of research
suggests that the current categorical diagnostic system
for eating disorders reflects neither the clinical reality
[20–23] nor does it provide meaningful information
about severity of illness or prognosis [24, 25]. Thus, clin-
ical staging can be viewed as a middle ground solution
between a categorical and dimensional view of illness.
However there have been limited attempts to develop
empirically supported measures and models of severity
and how, or if, this may be operationalised within a sta-
ging model. The empirical literature on AN generally pro-
vides insight into which symptoms may be candidate
variables contributing to severity. For example, key to the
notion of severity is the conferring of a poorer outcome or
prognosis for an individual as the illness increases in its
‘severity’. Not all features of AN have been appropriately
examined for their prognostic value, but there are a num-
ber of key symptoms in AN that have been found to be as-
sociated with poorer outcome or prognosis, including
body weight and weight history [26–28], duration of ill-
ness [27, 29], age at onset [27], drive for thinness [30, 31],
restrictive eating [32], body image disturbance [33, 34],
motivation for change [35], depression [36, 37], obsession-
ality [27, 33], purgative behaviours [27], menstrual func-
tion [38, 39] & medical complications [40, 41].
To our knowledge, only one other partly validated instru-
ment exists that explicitly attempts to assess AN illness se-
verity. The Short Evaluation of Eating Disorders (SEED) by
Bauer et al. [42] assesses severity, rating AN on a 4 stage
model from ‘not present’ (0) to ‘extreme’ (3), based on the
three DSM-IV criteria of AN – weight, fear of weight gain
and distortion of body image, but does not allow for a com-
prehensive evaluation of all of the clinical features pur-
ported to contribute to severity as described above. While
these three (one physical, and two psychological) symp-
toms are undeniably central to the illness, data which
differentiates these three symptoms from all others as
the strongest indicators of severity is lacking.
To address this need for a method to assess the fuller
range of AN symptomatology along the continuum of
severity, our group developed an instrument to assess
symptoms of AN commonly associated with prognosis
and outcome [43]. The full development of the instru-
ment has been published elsewhere [43] and is described
in Additional file 1: including the seven illness domains
it assesses. Using this empirically developed measure of
severity (Clinician Administered Staging Instrument for
Anorexia Nervosa (CASIAN) [43]), in this paper we
undertake the first exploratory analysis of a staging
model for AN, to determine if there is evidence to sup-
port further investigation of this conceptualisation in
AN. As a conservative approach in applying staging to a
novel area, our group have proposed a four stage model,
in-line with all prior staging models in mental health
and previous attempts in this illness group (described
above). As a result we conceptualised the spectrum of
AN-like disorders along a continuum of severity with
Stage 1 signifying mild or incipient AN, Stage 2 moder-
ate AN, Stage 3 severe AN and Stage 4 extremely severe
AN [43, 44]. Utilising CASIAN severity scores we use
receiver operating curve (ROC) analysis to empirically
derive cut-off scores for a four-stage model of illness.
Further, we undertake preliminary exploration of the
concurrent validity of the ‘stages’ and existing markers of
illness severity such as treatment intensity and diagnosis,
as well as explore movement between stages over a six
month period in a clinical population.
Specifically, we hypothesise that more severe stages of ill-
ness will be associated with more intensive treatment mo-
dalities and less severe stages of illness with less intensive
treatment. Further, given the more stringent criteria around
extent of weight loss, and menses loss in DSM-IV-R full-
criteria AN, along with existing data to suggesting AN and
DSM-IV-R EDNOS are an a continuum with AN repre-
senting the severe end [24, 45], we hypothesise that partici-
pants with more severe stages of illness are more likely to
meet full-criteria, than those with milder stage illness.
Method
Procedure
Participants (n = 171) were from the original cohort
extensively described elsewhere in the development of
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the CASIAN [44] including the description of recruit-
ment sites and recruitment method. To recruit a suffi-
cient sample with 6-month follow-up (Time 3) data and
reduce participant burden, the original data collection
for the CASIAN involved a cross sectional (n = 68) and
a longitudinal (n = 103) condition. Information was not
collected on the number or nature of persons who
refused to participate in the study.
DSM-IV-R diagnostic criteria were used to identify
individuals with AN eligible for participation in the
study as this was the diagnostic system version in com-
mon use in recruitment sites at that time. To capture
the full spectrum of illness severity including persons in
partial recovery or in the early stages of illness not yet
meeting full criteria, individuals with EDNOS were
included in the study. Ricca et al. [21] adjusted DSM-IV
criteria for EDNOS -Anorexia Nervosa subtype (EDNOS-
AN) were used to determine eligible for the study. That is,
these particular participants met all criteria for AN except
criterion D (EDNOS-AN(m)), and/or all criteria for AN
except criterion A (EDNOS-AN(w)). All subjects were
diagnosed by the Primary Clinicians at each site following
routine interview and assessment. For reference purposes,
and interpretability of data in the light of changes to the
diagnostic system, all participants in the study were reclas-
sified according to DSM 5 diagnostic criteria. As both the
percentage weight criteria and the menstrual criteria for
AN were removed in DSM 5, it should be noted that all
171 participants in this study meet full criteria for AN
under the DSM 5 system. In demographic tables both
classification systems are reported for the reference of the
reader. All analysis of the data retains use of the diagnostic
system in use at the time of data collection, DSM-IV-R.
In the cross sectional condition, the participant’s
Primary Clinician completed a Clinician Rating of Illness
Severity on a 5 point likert scale from 0 to 4, where zero
indicated no illness and 4 indicated extremely severe
illness. Those in the longitudinal condition were readmi-
nistered the CASIAN a further 2 times at 3 month
follow-up (Time 2) and 6 month follow-up (Time 3). No
data from the Time 2 collection is used here as 3 months
was deemed too short a time frame for this analysis. We
report only on data collected at Baseline (Time 1) and
6 month follow-up (Time 3). The research was reviewed
and approved by the relevant Ethics Committees at each re-
cruitment site, and all participants gave informed consent.
Participant characteristics
The mean age of the total sample was 24.39 years
(SD = 8.05; range = 16–58), with a mean Body Mass
Index (BMI = kg/m2) at admission into the study of
16.46 (SD = 2.32; range = 9.47–23.63). The mean dur-
ation of illness for the total sample was 7.97 years
(SD = 7.55; range = 0–38). 43.3% of participants met
DSM-IV-R full-criteria for AN, 56.7% met Ricca et al.,
[25] adjusted criteria for EDNOS-AN. Of these 23.4%
failed to meet the menstrual criteria and the remaining
33.3% failed to meet the weight criteria. Approximately
half (50.9%) of the sample were characterised as having
an anorexic illness of the restricting variety, while 49.1%
were classified as the binge/purging type [46]. Table 1
shows the characteristics for the study sample as a whole
and the samples from the two study arms, inclusive of
reference to comparable classification status under DSM
5 diagnostic criteria.
Measures
The CASIAN is a 34 item clinician administered inter-
view that assesses seven general domain areas: weight/
weight history, onset and duration of illness, dietary
control, compensatory behaviours, psychological status
(including depression, obsessionality and motivation for
change), physical status and egosyntonic features. Twenty-
three items compute a validated severity score [43]. (see
Additional file 1: for sample items).
Clinician Rating of Severity: In the absence of a
validated instrument other than the CASIAN to assess
illness severity at the time of data collection, and the
availability solely of instruments that were validated
either to diagnose only (i.e., categories as ‘ill’ or not ‘ill’)
or to assess the extent of a single or several features in
AN, an expert clinician rating of whole of illness sever-
ity, was chosen as an anchor point for examining stages
in the first instance. This type of ‘severity rating’ forms
routine practice at specialist centres recruiting to the trial.
The Clinician Rating of Severity is a Primary Clinicians
assessment of the severity of the person’s AN on a 5 point
likert scale from zero (0) through to four (4) where zero
represents no illness and four represents extremely severe
illness. The extremes and mid-point of the scale have an-
chor points describing features of an illness at this level of
severity, to guide the respondent in their choice. All clini-
cians participating in the study were highly experienced
experts in AN (all >20 years experience). The Clinician
Rating of Severity was significantly correlated with
scores on the CASIAN at baseline (r = .431, p < .01)
and Patients Rating of their Severity of Illness on the same
likert scale (r = .417, p < .01) (see Additional file 2: for
copy of rating scale).
Statistical analysis
The utility of dividing total scores on the CASIAN into
stages of illness according to severity was examined by
receiver operating curve (ROC) analysis assessing the re-
lationship between the sensitivity and 1-specificity of
each stage of the CASIAN. Chi-square assessed the con-
current validity of each stage against treatment intensity
categories and AN sub-types, and explored movement
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between stages over time. Post-hoc adjusted residual
analyses were conducted to explore the relative contri-
bution of cells to the chi square analysis.
All data were analysed using SPSS version 23.
Results
Overview
The data analytic plan involved several sequential steps.
First, appropriate stage cut-off scores were established,
and the total sample divided according to stage. There-
after we explored the concurrent validity of the staging
model by examining the relationships between the pro-
posed stages and existing markers of illness severity –
intensity of treatment modality and DSM-IV-R diagno-
sis. Finally short-term predictive validity of the stages
was examined by assessing stage of illness at baseline
and 6-month follow-up.
Sensitivity and specificity analysis
To explore appropriate cut-off scores for each stage of
illness, the ratings for all cases in the cross-sectional
condition (n = 68) that had a Clinician Rating of Illness
Severity (n = 67), were divided into stages 1 (.5 through
1.49), 2 (1.5 through 2.49), 3 (2.5 through 3.49), and 4
(3.5+). A ROC analysis was then run to determine the
best cut-points for total scores in distinguishing stage 1
vs. 2,3, 4 (cut point for stage 2), 1, 2 vs. 3, 4 (cut point
for stage 3), and 1, 2, 3 vs. 4 (cut point for stage 4).
Figure 1 and Table 2 show the ROC curve results for
distinguishing the stages. The ROC curve shows the sen-
sitivity (% of those rated as another stage by clinicians at
or above the CASIAN Total Score cutoff ) and specificity
(% of those rated as the desired stage by clinicians below
the CASIAN Total Score cutoff ) for every possible
CASIAN score. The area under the curve (AUC) for the
ability of the CASIAN to distinguish Stage 1 from all
other stages was 0.678 suggesting that the CASIAN is
better than chance at distinguishing individuals at Stage
1 illness and has at least some ability to discriminate be-
tween Stage 1 and the other Stages of illness. However
this finding did not reach significance (p = 0.064).
The AUC for ability of the CASIAN to distinguish
Stage 1 and 2 from Stages 3 and 4 (i.e. the cut-off
point for Stage 2) was 0.706, reaching (p = 0.004).
This finding would suggest that the CASIAN is better
than chance at distinguishing individuals at Stage 2
illness and has the ability to discriminate between
Stage 2 and the other Stages of illness.
The AUC for ability of the CASIAN to distinguish
Stage 1, 2, 3 from Stage 4 illness (i.e. the cut-off score
Table 1 Characteristics of the study sample
Total sample Study sample 1 (Longitudinal) Study sample 2 (Cross-sectional)
Mean (SD) Mean (SD) Mean (SD)
Age (yrs) 24.39 (8.05) 25.34 (8.63) 22.96 (6.89)
BMI 16.46 (2.32) 16.08 (2.16) 17.03 (2.46)
Duration of Illness (yrs) 7.97 (7.55) 8.69 (7.95) 6.85 (6.78)
DSM 5 AN 100% 100% 100%
DSM-IV-R Full Criteria AN (%) 43.3% 46.6% 38.2%
EDNOS-AN(m) (%) 23.4% 26.2% 19.1%
EDNOS-AN(w) (%) 33.3% 27.2% 42.7%
Restricting subtype (%) 50.9% 51.5% 50%
Binge/Purging subtype(%) 49.1% 48.5% 50%
Fig. 1 ROC curve for CASIAN score distinguishing between stages
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for stage 3) was 0.674 with p = 0.070. This finding would
suggest that the CASIAN has at least some ability to dis-
criminate between Stage 4 and the other Stages of illness.
Although approaching significance the test did not reach
it suggesting the CASIAN is not statistically significantly
better than making this decision based on pure chance.
Table 2 shows the curve coordinates (sensitivity and
specificity) for each of the three cut-off points for total
CASIAN scores selected in the sample of 67 cases with
Clinician Ratings of Illness Severity. To maximise sensi-
tivity and specificity of the instrument for identifying
each stage a cut-off score on the CASIAN of 34.50 as the
lower limit for Stage 2 was selected, 48.50 as the lower
limit for Stage 3 and 52.5 as the lower limit for Stage 4.
Frequency of stages
To explore the potential utility of stages within AN, the
above determined cut-off points suggested by ROC were
then applied to the entire original cohort (n = 171).
Validity of the proposed stages of illness
Concurrent Validity: Stage of illness and treatment
modality
Figure 2 depicts the relationship between ‘stage’ of ill-
ness and intensity of treatment modality. The percentages
of participants at different stages of illness according to
the treatment type they are engaged in is also outlined in
Table 3. Figure 2 shows that for the milder stages of illness
(Stage 1 and 2) a greater percentage were engaged in less
intensive treatment (outpatient therapy) as depicted by
the elevated red bars in these stages. For those in the more
severe stages of illness (Stage 3 and 4) a greater percentage
were engaged in more intensive treatment (inpatient ther-
apy), as indicated by the elevated green bars in these
stages. A chi square analysis of the differences in treatment
modality utilised by individuals at different stages of illness
was found to be significant, (χ2 [df = 9, n = 171] =32.47,
p = .000). A post hoc test using the adjusted residual
method [47, 48] was conducted to determine which cells
made the largest contribution to the significant chi square,
p values were calculated for each adjusted residual (z
score) and residuals adjusted for the type 1 error rate
(∝/16 as 16 cells being tested) producing a significance
level of ∝ = .00031.
Using this significance level, in Table 3 the p value
from three cells (bold, underlined) reach significance.
For those individuals in Stage 2 illness there was a sig-
nificantly smaller number receiving inpatient treatment.
For those in Stage 4 illness the pattern was reversed with
significantly more in inpatient treatment and less in
outpatient.
Concurrent validity: DSM-IV-R diagnosis and stage
The relationship between stage of illness and DSM-IV-
R diagnosis was also examined. Figure 3 depicts the
overall pattern of results when the sample was divided
according to the stage of illness and primary eating dis-
order diagnosis at the time of first assessment.
As the figure and percentages in Table 4 suggest, those
individuals in the milder stages of illness (Stage 1 and 2)
tended to be diagnosed as DSM-IV-R EDNOS cases, and
the majority failed to meet the weight criteria, as indicated
by the elevated yellow bars in these stages. Whereas, par-
ticipants in the more severe stages of illness (Stage 3 and
4) tended to be diagnosed with full syndrome AN, as indi-
cated by the elevated blue bars in these stages. A chi
square analysis of the differences in diagnoses across the
Table 2 ROC curve results
Area under the curve Coordinates of the curve
Stage Area Sig Positive if ≥ to Sensitivity 1-Specificity
1 vs 2,3,4 0.678 0.064 34.50 .929 .455
1,2 vs 3,4 0.706 0.0004 48.50 .694 .290
1,2,3 vs 4 0.674 0.070 52.50 .545 .304
Fig. 2 Stages of illness and types of treatment
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Stages of Illness at first assessment was significant,
(χ2 [df = 6, n = 171] =35.322, p = .000). A Post hoc
test of the adjusted residuals was conducted, p values
were calculated for each adjusted residual (z score)
and residuals adjusted for the type 1 error rate (∝/12
as 12 cells being tested) producing a significance level
of ∝ = .00042.
Utilising this significance level, in Table 4, we can see
that the p value from six cells reached significance (bold,
underlined). For those individuals in the milder stages
(Stage 1 and 2), there was a significantly smaller number
who met full-criteria DSM-IV-R AN and significantly
larger proportions diagnosed with EDNOS-AN (fail
weight criteria). In the most severe stages of illness
(Stage 4) significantly more were diagnosed with DSM-
IV-R full-criteria AN and less with EDNOS-AN (fail
weight criteria).
Predictive Validity: Baseline Stage of Illness compared
to 6-month follow-up
Finally movement between stages of illness from baseline
to 6 month follow-up was explored for those participants
in the longitudinal condition (n = 103) who completed a
staging assessment at 6 month follow-up (n = 74).
Figure 4 depicts these results, with the percentages
also outlined in Table 5. Individuals in Stage 1, 3 and 4
were more likely to still be classified within the same
stage at 6 month follow-up. Stage of Illness at Time 3
was significantly predicted by Stage of Illness at Time 1
(χ2 [df = 9, n = 74] =28.86, p = .001). A post hoc test
using the adjusted residual method was conducted, p values
were calculated for each adjusted residual (z score) and
residuals adjusted for the type 1 error rate (∝/16 as 16 cells
being tested) producing a significance level of ∝ = .00031.
Utilising this significance level, from Table 5, three
cells reached significance (bold, underlined). For those
individuals in Stage 1, 3 and 4 there was a significantly
larger proportion in the same Stage of Illness at 6 month
follow-up.
Discussion
While several AN staging models have been proposed,
as far as we are aware our work goes one step further to
empirically examine staging in a dataset of people with
AN and explore if this conceptualisation of illness has
potential. Despite the relatively large sample size for a
rare illness, the present examination needs be regarded
as exploratory in nature, examining the potential utility
of a provisional model. As is the case with all innova-
tions, this study is intended to stimulate further testing
of the model through both replication and extension
within further large samples. We especially encourage
other independent research groups to empirically scru-
tinise the model.
Table 3 Relationship between stage 1 and treatment modality
Treatment type
Nil Outpatient Day program Inpatient
Stage 1 Count 2 8 2 5
% 11.8 47.1 11.8 29.4
Adj. Resid. 0.6 1.5 0.6 −2.0
P value 0.55 0.13 0.55 0.05
Stage 2 Count 7 23 7 13
% 14 46 14 26.0
Adj. Resid. 1.8 2.7 1.8 −4.5
P value 0.07 0.01 0.07 0.00
Stage 3 Count 1 8 1 13
% 4.3 34.8 4.3 56.5
Adj. Resid. −0.7 0.4 −0.7 0.4
P value 0.48 0.69 0.48 0.69
Stage 4 Count 4 14 4 59
% 4.9 17.3 4.9 72.8
Adj. Resid. −1.5 −3.7 −1.5 5.0
P value 0.13 0.00 0.13 0.00
Fig. 3 Stage of illness and diagnosis
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While a four-stage model (derived from CASIAN scores)
may possess some ability to detect cases at different stages
of illness, only one of the three stage cut-off investigations
reached significance. That is, between milder stages of
illness 1–2 and more severe stages 3–4.The ability to dis-
tinguish Stage 1 from all others and Stage 4 from all others
still warrants further investigation with larger and ideally
multi-site studies.
As a way of investigating if the proposed staging
model correlated with existing markers of illness severity
(like intensity of treatment and full-syndrome versus
partial-syndrome diagnosis) it was hypothesised that
people with more severe stages of illness would engage
with more intensive treatment options and the study
found some support for this. The residual analysis sug-
gested the largest contributions to this were in persons
with the most severe illness (Stage 4), who were signifi-
cantly more likely to be engaged in hospital treatment
and less likely to be in outpatient care. In addition there
was some evidence to suggest that persons at a milder
stage of illness, Stage 2, were significantly less likely to
be in inpatient care. The failure to find significant con-
tributions from other stages of illness may be a result of
sample size limitations, because recruitment was most
successful through treatment facilities this sample has a
larger number of participants in the more severe stages
of illness. Alternatively, it could reflect the lack of treat-
ment options available to many individuals with AN.
Table 4 Relationship between stage and diagnosis
Diagnosis
AN EDNOS - AN (Fail Menstrual) EDNOS - AN (Fail Weight)
Stage 1 Count 1 5 11
% 5.9 29.4 64.7
Adj. Resid. −3.3 0.6 2.9
P value 0.00 0.55 0.00
Stage 2 Count 11 13 26
% 22 26 52
Adj. Resid. −3.6 0.5 3.3
P value 0.00 0.62 0.00
Stage 3 Count 15 3 5
% 65.3 13.0 21.7
Adj. Resid. 2.3 −1.3 −1.3
P value 0.02 0.19 0.19
Stage 4 Count 47 19 15
% 58 23.5 18.5
Adj. Resid. 3.7 .0 −3.9
P value 0.00 1.00 0.00
Fig. 4 Stage of illness at baseline (Time 1) and 6 month follow-up (time 3)
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As hypothesised, support was found for stages of
illness to reflect DSM-IV-R diagnoses in that people in
the milder stages of illness, both Stage 1 and 2, were
more likely to be diagnosed with DSM-IV-R nosology
EDNOS, and those in Stage 3 and 4 illness more likely to
be assigned full-criteria diagnosis. Other studies have con-
firmed such an understanding of DSM-IV-R EDNOS-AN
cases. For example, a large meta-analytic review compar-
ing EDNOS and the full syndrome ED cases also con-
cluded that full-syndrome AN represents the severe end
of a continuum that is likely to include EDNOS ill-
nesses at the milder end of this [24]. It should be noted
that application of DSM-5 diagnostic criteria to partici-
pants in this study saw all redefined as full-syndrome
AN according to DSM 5.
Successful staging in AN would have a number of clinical
and research uses. To be able to assess any presenting indi-
vidual against a number of empirically derived symptoms
known to accurately assess severity and predict prognosis
would have uses in treatment design, matching patients to
treatment, improving the client and carer experience and
understanding of the illness and the likely outcome, as well
as enabling streamlined research of participants at varying
stages of illness. Ideally with further research, a refined sub-
set of core symptoms could be identified to stage an indi-
vidual efficiently, match them with suitable treatments and
predict with some accuracy their prognosis, therefore the
range of variables examined in this study need further
examination and refinement to determine which illness
factors are the best markers and prognostics for the most
efficient staging model.
The ultimate utility of a staging model is arguably to
be able to predict outcome. This needs to be done over
the longer term ideally with assessment and ‘staging of
illness’ at the earliest possible point in presentation and
assessment of outcome over the long term. As a prelim-
inary exploration of a staging model and its relationship
to outcome, we found that, for those individuals in Stage
1, 3 and 4, there was a significantly larger proportion in
the same Stage of Illness at 6 month follow-up. This is a
very short follow-up period, and not one with participants
first assessed immediately after onset, so this finding may
well reflect that the time frame for assessment is too short
to assess illness trajectory. Further examination of the
prognostic utility of stages is worth further investigation
in large samples, over long follow-up periods.
Limitations
There are a number of limitations to the study, the first
of which is the need for a larger concurrently recruited
sample with a more even spread of illness severity.
Obtaining sufficient sample sizes of rare disorders is
always difficult and AN is an especially difficult popula-
tion to recruit. The recruitment strategy also introduced
a sampling bias in that people not receiving treatment
were underrepresented and it was not possible to control
for treatment and illness duration factors. Importantly
therefore, the staging concept should be explored cap-
turing those in the community, in very early in the ill-
ness trajectory, and then followed over a much longer
term. Inevitably, these may need to be multisite collabo-
rations and these are feasible..Finally in terms of sam-
pling, there may also have been an implicit bias amongst
those participants who agreed to participate in the study
or agree to long follow-up. For example, hospitalised
participants who more likely to agree to 6 months
follow-up may have been more welcoming of the diver-
sion (of participation) as opposed to those receiving out-
patient treatment who may have wanted less intrusion
into their life.
A second major limitation relates to the lack of any ‘gold
standard’ severity measures in AN at the time of data col-
lection in which to develop stage cut offs We needed to
develop a clinician rating of severity using highly experi-
enced clinicians but this was was deemed superior to any
existing ill/not ill diagnostic instrument or existing instru-
ments that measure single dimensions of illness. Cut-off
for stages using the CASIAN require examination using
other measures of illness severity, and further studies need
to expand upon the examination of a staging model using
other anchor points, and other statistical methods.
Conclusion
While the limitations of this study need to be addressed
in studies with larger consecutively recruited samples,
Table 5 Movement across stages from time 1 to time 3
Stage at Time 3 (6 months FU)
Stage 1 Stage 2 Stage 3 Stage 4
Stage 1 Count 4 0 0 0
% 100 0 0 0
Adj. Resid. 3.6 −1.2 −0.7 −1.7
P value 0.00 0.23 0.48 0.09
Stage 2 Count 7 6 2 4
% 36.8 31.6 10.5 21.1
Adj. Resid. 1.5 0.7 0.0 −1.9
P value 0.13 0.48 1.00 0.06
Stage 3 Count 1 3 4 3
% 9.1 27.3 36.4 27.3
Adj. Resid. −1.3 0.1 3.0 −0.9
P value 0.19 0.92 0.00 0.37
Stage 4 Count 6 10 2 22
% 15 25 5 55
Adj. Resid. −2.0 −0.1 −1.7 3.0
P value 0.05 0.92 0.09 0.00
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provisional support for the conceptualisation of illness
stages within the AN illness continuum was found here.
We were able to demonstrate an instrument to distin-
guish between milder and more severe stages of illness
and then relationships between these stages and relevant
illness factors. The current data can only be considered
as highly provisional but encouraging of further studies
in an area struggling with slow advances in improving
treatment outcomes. Capturing key aspects of illness
staging is one of the identified key goals in order to help
psychiatry potentially benefit from pathway models
proven so useful with some medical conditions [49, 50].
Time will tell if psychiatric classifications systems can be
enhanced by atriculating stages found to be clincially
useful.
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